Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?

Critical Reviews in Oncology/hematology
Laura CannellaFabio Efficace

Abstract

Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are crucial for a comprehensive evaluation of treatment effectiveness. A systematic review of randomized controlled trials (RCTs) with a PRO endpoint conducted in patients with leukemia and myelodysplastic syndromes (MDS) was performed. Eligible studies were evaluated independently, according to a pre-defined coding scheme, by two reviewers. Thirteen RCTs, enrolling overall 3380 patients were identified. There were four RCTs involving acute myeloid leukemia patients (AML), one with acute lymphoid leukemia (ALL), five with chronic lymphocytic leukemia (CLL) and three with MDS. Six RCTs accurately documented PRO methodology assessment and were thus considered likely to robustly inform clinical decision-making. Of these, three RCTs dealt with AML, two with CLL, one with MDS. A growing number of RCTs in leukemia and MDS have included a PRO component in recent years. Inclusion of PROs in RCTs is feasible and can provide unique information to facilitate clinical decision-making.

References

Nov 5, 2005·Leukemia·M KoenigsmannJ Frommer
Nov 11, 2006·Blood·Frederick R AppelbaumMartin S Tallman
Mar 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara F EichhorstUNKNOWN German CLL Study Group
May 11, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Hallek, M Hallek
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Barbara Eichhorst, Michael Hallek
Jun 17, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fabio EfficaceBernhard Holzner
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev
Feb 1, 2009·Expert Review of Hematology·Giovanni CaocciFabio Efficace
Nov 27, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Michael BrundageDeb Feldman-Stewart
Feb 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A WoyachJohn C Byrd
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Magnus BjörkholmPaul W Dickman
Dec 16, 2011·Leukemia & Lymphoma·Monica ElseUNKNOWN UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Trials Group
Mar 2, 2012·The New England Journal of Medicine·Charles L Bardes
Sep 19, 2012·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Michael BrundageMelanie Calvert
Oct 17, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan BaschSean Tunis
Dec 12, 2012·Leukemia·A K BurnettUNKNOWN United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup
Jun 26, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Donald Patrick
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Sep 13, 2013·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Fabio EfficaceFranco Mandelli
Oct 15, 2013·American Journal of Hematology·Liesbeth C de WreedeJohannes Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council

❮ Previous
Next ❯

Citations

Nov 26, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yan ChenGuoan Chen
Jul 9, 2016·Expert Review of Hematology·Sarah A BuckleyRoland B Walter
May 16, 2020·British Journal of Haematology·Ursula RochauReinhard Stauder
Aug 28, 2020·Journal of Patient-reported Outcomes·Jeremiah J TrudeauAdam Gater
Feb 13, 2020·Current Hematologic Malignancy Reports·Shimoli V BarotAaron T Gerds
Aug 9, 2020·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Dominik GolickiMaciej Niewada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.